当前位置: X-MOL 学术Gut › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy
Gut ( IF 23.0 ) Pub Date : 2022-09-01 , DOI: 10.1136/gutjnl-2021-326196
Zahra Jama Shire 1, 2 , Frederic Reicherz 2 , Sally Lawrence 1, 2 , Harjeev Sudan 1, 2 , Liam Golding 2 , Abdelilah Majdoubi 2 , Paul N Levett 3, 4 , Pascal M Lavoie 2 , Kevan Jacobson 2, 5
Affiliation  

We read with interest the recent findings by Kennedy et al , which concluded that infliximab (IFX) impairs antibody responses to a single dose of the mRNA-BNT162b2 SARS-CoV-2 vaccine in adult patients with IBD.1 2 Interestingly, another study showed that antibodies against SARS-CoV-2 diminish over time following infection in adult patients with IBD.3 In general, more robust antibody responses have been observed in adolescents compared with adults in the BNT162b2 vaccine trial.4 However, the true impact of immunosuppressant therapies on SARS-CoV-2 vaccine efficacy in paediatric IBD (PIBD) patients is unknown as they were excluded from the trials. Therefore, analysing vaccine responses directly in these patients is necessary to determine the best strategy.5 6 We undertook a study to evaluate immunogenicity of mRNA-based SARS-CoV-2 vaccines in PIBD patients treated with anti-TNF therapies. Given the urgent need for data, we herein present preliminary findings. The study prospectively enrolled PIBD patients 12–17 years, treated with anti-TNF agents either alone or in combination with an immunomodulator, who received the BNT162b2 vaccine. Serum antibody levels for (spike protein, receptor-binding domain (RBD) and nucleocapsid protein) were measured at baseline, 28 days and 3 months after the first vaccine dose. Antibody responses were assessed using the V-PLEX SARS-CoV-2 Panel 2 (IgG) assay (Meso Scale …

中文翻译:

接受抗 TNF 治疗的儿童炎症性肠病患者对 BNT162b2 SARS-CoV-2 疫苗的抗体反应

我们感兴趣地阅读了 Kennedy 等人最近的研究结果,其结论是英夫利昔单抗 (IFX) 会削弱成人 IBD 患者对单剂 mRNA-BNT162b2 SARS-CoV-2 疫苗的抗体反应。1 2 有趣的是,另一项研究表明SARS-CoV-2 抗体在成年 IBD 患者感染后会随着时间的推移而减少。3 一般来说,在 BNT162b2 疫苗试验中,与成人相比,在青少年中观察到的抗体反应更强烈。4 然而,免疫抑制剂疗法的真正影响关于 SARS-CoV-2 疫苗对小儿 IBD (PIBD) 患者的疗效尚不清楚,因为他们被排除在试验之外。因此,有必要直接分析这些患者的疫苗反应,以确定最佳策略。5 6 我们进行了一项研究,以评估基于 mRNA 的 SARS-CoV-2 疫苗在接受抗 TNF 治疗的 PIBD 患者中的免疫原性。鉴于对数据的迫切需求,我们在此提出初步调查结果。该研究前瞻性招募了 12-17 岁的 PIBD 患者,这些患者接受了 BNT162b2 疫苗的单独或联合免疫调节剂的抗 TNF 药物治疗。(刺突蛋白、受体结合结构域 (RBD) 和核衣壳蛋白)的血清抗体水平在基线、第一次疫苗接种后 28 天和 3 个月时测量。使用 V-PLEX SARS-CoV-2 Panel 2 (IgG) 测定法(Meso Scale … 接受 BNT162b2 疫苗的患者单独或与免疫调节剂联合使用抗 TNF 药物进行治疗。(刺突蛋白、受体结合结构域 (RBD) 和核衣壳蛋白)的血清抗体水平在基线、第一次疫苗接种后 28 天和 3 个月时测量。使用 V-PLEX SARS-CoV-2 Panel 2 (IgG) 测定法(Meso Scale … 接受 BNT162b2 疫苗的患者单独或与免疫调节剂联合使用抗 TNF 药物进行治疗。(刺突蛋白、受体结合结构域 (RBD) 和核衣壳蛋白)的血清抗体水平在基线、第一次疫苗接种后 28 天和 3 个月时测量。使用 V-PLEX SARS-CoV-2 Panel 2 (IgG) 测定法(Meso Scale …
更新日期:2022-08-11
down
wechat
bug